BioSpace News Archive

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced the appointment of Mark Novara as Executive Vice President and Chief Commercial Officer, effective November 13, 2023.

Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30, 2023 on Monday, November 6, 2023 after the close of the US market.

ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of October 31, 2023, grants of non-qualified stock options to purchase 2,650 shares of its common stock and restricted stock units covering 1,800 shares of its common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to a new employee.

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Ocuphire Pharma, Inc. announced that the independent members of its Board of Directors approved equity awards under Ocuphire’s 2021 Inducement Plan, as a material inducement to George Magrath, M.D., M.B.A., M.S., the Company’s newly appointed Chief Executive Officer and member of the Board, in connection with his employment with the Company effective on November 1, 2023.

Mirion, a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, announced results for the third quarter ended September 30, 2023.

AAPS Salary Survey Shows 6.7% Compensation Increase Since 2022

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2023 on Wednesday, November 8, 2023, after the market closes.

The Board of Directors of Swedish Orphan Biovitrum AB has, as previously communicated, on 31 October 2023 resolved to issue redeemable and convertible series C shares and to, conditional upon subscription and payment from Svenska Handelsbanken AB, repurchase all issued series C shares, to secure Sobi’s obligations under the outstanding incentive programmes.

Contego Medical Inc., a company dedicated to improving patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease, today announced the presentation of late-breaking clinical results from the PERFORMANCE II carotid stent trial at the annual VIVA (Vascular InterVentional Advances) multidisciplinary vascular education conference.